Symposia: Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Biological therapies, Antibody Therapy, adult, Translational Research, Non-Biological therapies, Bispecific Antibody Therapy, elderly, Clinical Research, Chemotherapy, Combination therapy, Diseases, Therapies, Adverse Events, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Biological therapies, Antibody Therapy, adult, Translational Research, Non-Biological therapies, Bispecific Antibody Therapy, elderly, Clinical Research, Chemotherapy, Combination therapy, Diseases, Therapies, Adverse Events, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 2:00 PM-3:30 PM
265-268
(Ernest N. Morial Convention Center)
Moderators:
Emily K Curran, MD, University of Cincinnati Cancer Center
and
Shella Saint Fleur-Lominy, MD, PhD, New York University Grossman School of Medicine
Disclosures:
Curran: Amgen: Consultancy, Other: Participation in advisory board; Incyte: Consultancy, Other: Participation in advisory board; Kite: Consultancy, Other: Participation in advisory board; Pfizer: Consultancy, Other: Participation in advisory board; Tempus: Consultancy, Other: Participation in advisory board; Servier: Consultancy, Honoraria, Other: Participation in advisory board; participation in expert panel guidelines.
The session includes abstracts for both pediatric and adult patients with ALL from early phase to randomized phase III therapeutic trials, excluding transplant and cellular therapies.
2:00 PM
2:15 PM
2:30 PM
2:45 PM
3:00 PM
3:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH